Dyne Therapeutics
DYN
15.97
+0.57
+3.70%
Dyne Therapeutics
US · DYN
#2540 by market cap
Listed 2020
15.97
+0.57
+3.70%
Live - 5344 symbols - heartbeat 124s ago
· 2026-10-08 08:23
Pre-market
15.70
-1.69%
After-hours
16.00
+0.19%
- Market cap
- 2.98B
- P/E (TTM)i
- -4.90
- P/Bi
- 4.25
- EPSi
- -3.47
- Div yieldi
- 0.00%
- 52W posi
- 17%
Reader sentiment
Are you bullish or bearish on DYN?
Anonymous reader poll. Unscientific, not investment advice.
Revenue annual, last 8 years
Key ratios & quality
- Enterprise valuei
- 2.03B
Income statement
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- | -- | -- | -- |
| Gross profit | -- | -- | -- | -- | -- | -- | -- | -- |
| Selling & admin expenses | 517.00K | 2.79M | 13.45M | 28.72M | 28.20M | 31.40M | 62.48M | 69.85M |
| Research & development | 4.28M | 11.04M | 45.20M | 121.31M | 142.76M | 210.76M | 281.41M | 398.33M |
| Operating profit | -4.80M | -13.83M | -58.65M | -150.03M | -170.96M | -242.16M | -343.89M | -468.18M |
| Pretax profit | -4.81M | -14.86M | -59.44M | -149.29M | -168.10M | -235.94M | -317.42M | -446.21M |
| Tax | -- | -- | -- | -- | -- | -- | -- | -- |
| Net profit | -4.81M | -14.86M | -59.44M | -149.29M | -168.10M | -235.94M | -317.42M | -446.21M |
| Basic EPS | 0 | -1 | -4 | -3 | -3 | -4 | -3 | -3 |
| Diluted EPS | -0.47 | -1.16 | -4.13 | -2.93 | -3.23 | -3.95 | -3.37 | -3.47 |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- | -- |
| Gross profit | -- | -- | -- | -- | -- | -- |
| Selling & admin expenses | 15.93M | 16.56M | 16.67M | 20.70M | 24.39M | 29.49M |
| Research & development | 106.45M | 99.24M | 97.22M | 95.43M | 100.89M | 152.17M |
| Operating profit | -122.37M | -115.79M | -113.89M | -116.13M | -125.28M | -181.66M |
| Pretax profit | -115.36M | -110.86M | -108.04M | -111.96M | -120.85M | -178.56M |
| Tax | -- | -- | -- | -- | -- | -- |
| Net profit | -115.36M | -110.86M | -108.04M | -111.96M | -120.85M | -178.56M |
| Basic EPS | -1 | -1 | -1 | -1 | -1 | -1 |
| Diluted EPS | -1.05 | -0.97 | -0.76 | -0.76 | -0.73 | -1.08 |
Balance sheet
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Total current assets | 8.16M | 14.76M | 349.09M | 382.39M | 265.59M | 129.38M | 659.28M | 1.13B |
| Cash & ST investments | 8.12M | 14.63M | 345.31M | 376.57M | 256.01M | 123.10M | 642.27M | 1.11B |
| Inventory | -- | -- | -- | -- | -- | -- | -- | -- |
| Total assets | 8.27M | 16.44M | 353.33M | 425.66M | 306.33M | 165.08M | 691.23M | 1.19B |
| Total current liabilities | 711.00K | 2.36M | 10.97M | 28.72M | 28.09M | 51.10M | 42.26M | 50.63M |
| Short-term debt | -- | -- | -- | 3.89M | 4.61M | 4.72M | 4.85M | 5.00M |
| Long-term debt | -- | -- | -- | -- | -- | -- | -- | 148.92M |
| Total liabilities | 13,147,000.00 | 2,400,000.00 | 10,967,000.00 | 57,466,000.00 | 53,961,000.00 | 73,790,000.00 | 61,396,000.00 | 214,829,000.00 |
| Total equity | -4.88M | 14.04M | 342.37M | 368.20M | 252.36M | 91.29M | 629.84M | 972.13M |
| Retained earnings | -4.89M | -19.75M | -79.18M | -228.47M | -396.57M | -632.51M | -949.93M | -1.40B |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Total current assets | 689.50M | 697.95M | 806.26M | 1.13B | 1.02B | 937.89M |
| Cash & ST investments | 677.49M | 683.93M | 791.89M | 1.11B | 972.16M | 898.48M |
| Inventory | -- | -- | -- | -- | -- | -- |
| Total assets | 721.07M | 728.99M | 867.06M | 1.19B | 1.08B | 994.01M |
| Total current liabilities | 33.88M | 41.47M | 59.85M | 50.63M | 51.25M | 78.03M |
| Short-term debt | 5.11M | 5.00M | 5.04M | 5.00M | 5.03M | 5.37M |
| Long-term debt | -- | 98.81M | 99.15M | 148.92M | 149.38M | 199.33M |
| Total liabilities | 52,101,000.00 | 157,547,000.00 | 175,276,000.00 | 214,829,000.00 | 214,895,000.00 | 291,862,000.00 |
| Total equity | 668.97M | 571.45M | 691.78M | 972.13M | 865.06M | 702.15M |
| Retained earnings | -1.07B | -1.18B | -1.28B | -1.40B | -1.52B | -1.70B |
Cash flow
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -4.16M | -11.83M | -46.51M | -119.56M | -153.65M | -188.16M | -292.37M | -403.21M |
| Depreciation & amortization | 24.00K | 271.00K | 700.00K | 1.09M | 1.68M | 1.67M | 1.67M | 2.05M |
| Free cash flow | -4.30M | -13.48M | -47.67M | -123.18M | -156.71M | -188.89M | -294.75M | -423.92M |
| Dividends paid | -- | -- | -- | -- | -- | -- | -- | -- |
| Stock buybacks / issuance | 7.00K | 0 | 246.39M | 157.24M | 36.86M | 52.37M | 773.05M | 734.61M |
| Ending cash balance | 8.12M | 14.63M | 303.15M | 203.52M | 174.47M | 123.94M | 437.39M | 895.74M |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Operating cash flow | -105.89M | -94.70M | -90.78M | -111.83M | -144.92M | -130.29M |
| Depreciation & amortization | 502.00K | 503.00K | 523.00K | 521.00K | 550.00K | 560.00K |
| Free cash flow | -106.87M | -94.76M | -109.96M | -112.32M | -145.14M | -131.80M |
| Dividends paid | -- | -- | -- | -- | -- | -- |
| Stock buybacks / issuance | 140.65M | 0 | 215.80M | 378.15M | 0 | 0 |
| Ending cash balance | -- | -- | 575.63M | 895.74M | -- | -- |
Returns & efficiency
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| ROE %i | -- | -- | -36.13 | -42.02 | -54.18 | -137.31 | -88.03 | -55.71 |
| ROA %i | -58.19 | -109.59 | -32.15 | -38.33 | -45.93 | -100.10 | -74.14 | -47.52 |
| ROIC %i | -- | -- | -35.93 | -38.68 | -50.03 | -121.32 | -89.15 | -52.35 |
| 5-year avg ROE %i | -- | -- | -- | -- | -- | -- | -71.54 | -75.45 |
| EBIT margin %i | -- | -- | -- | -- | -- | -- | -- | -- |
| FCF / sales %i | -- | -- | -- | -- | -- | -- | -- | -- |
| Current ratioi | 11.47 | 6.26 | 31.83 | 13.31 | 9.46 | 2.53 | 15.60 | 22.25 |
| Quick ratioi | 11.43 | 6.21 | 31.49 | 13.11 | 9.11 | 2.41 | 15.20 | 21.94 |
| Debt / assetsi | -- | -- | 0.00 | 7.67 | 9.95 | 16.61 | 3.47 | 14.25 |
| LT debt / equityi | -- | -- | -- | 7.81 | 10.25 | 24.86 | 3.04 | 16.89 |
| Interest coveragei | -- | -- | -149.09 | -- | -- | -- | -- | -71.06 |
| Revenue CAGR (3Y) %i | -- | -- | -- | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Net income CAGR (3Y) %i | -- | -- | -- | -- | -- | -- | -- | -- |
| FCF CAGR (3Y) %i | -- | -- | -- | -- | -- | -- | -- | -- |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| ROE %i | -64.01 | -61.32 | -60.66 | -55.71 | -58.89 | -81.57 |
| ROA %i | -59.05 | -53.11 | -51.81 | -47.52 | -50.16 | -60.29 |
| ROIC %i | -66.53 | -59.39 | -58.81 | -52.35 | -54.79 | -66.57 |
| 5-year avg ROE %i | -- | -- | -- | -- | -- | -- |
| EBIT margin %i | -- | -- | -- | -- | -- | -- |
| FCF / sales %i | -- | -- | -- | -- | -- | -- |
| Current ratioi | 20.35 | 16.83 | 13.47 | 22.25 | 19.92 | 12.02 |
| Quick ratioi | 20.00 | 16.49 | 13.23 | 21.94 | 18.97 | 11.51 |
| Debt / assetsi | 3.24 | 16.61 | 13.89 | 14.25 | 15.62 | 22.05 |
| LT debt / equityi | 2.72 | 20.31 | 16.69 | 16.89 | 18.92 | 30.45 |
| Interest coveragei | -- | -- | -- | -71.06 | -42.46 | -33.87 |
| Revenue CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
| Net income CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
| FCF CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
Quote time 2026-10-08 08:23:22 · For reference only, not investment advice and not tailored to your situation.